Literature DB >> 23610124

Performance of salivary cortisol in the diagnosis of Cushing's syndrome, adrenal incidentaloma, and adrenal insufficiency.

Filippo Ceccato1, Mattia Barbot, Marialuisa Zilio, Sergio Ferasin, Gianluca Occhi, Andrea Daniele, Sara Mazzocut, Maurizio Iacobone, Corrado Betterle, Franco Mantero, Carla Scaroni.   

Abstract

OBJECTIVE: Salivary cortisol has recently been suggested for studies on the hypothalamic-pituitary-adrenal (HPA) axis. The lack of circadian rhythm is a marker of Cushing's syndrome (CS), and some authors have reported that low salivary cortisol levels may be a marker of adrenal insufficiency. The aim of our study was to define the role of salivary cortisol in specific diagnostic settings of HPA axis disease. SUBJECTS AND METHODS: We analyzed morning salivary cortisol (MSC) and late-night salivary CORTISOL (LNSC) levels in 406
SUBJECTS: 52 patients with Cushing's disease (CD), 13 with ectopic CS, 17 with adrenal CS, 27 with CD in remission (a mean follow-up of 66±39 months), 45 with adrenal incidentaloma, 73 assessed as having CS and then ruled out for endogenous hypercortisolism, 75 with adrenal insufficiency, and 104 healthy subjects.
RESULTS: A LNSC value above 5.24  ng/ml differentiated CS patients from controls with high sensitivity (96.3%) and specificity (97.1%); we found higher LNSC levels in ectopic CS patients than in CD patients. We found no difference in MSC and LNSC levels between patients with CD in remission and healthy subjects. Both MSC and LNSC levels were higher in patients with adrenal incidentaloma than in healthy controls. A MSC value below 2.65 ng/ml distinguished patients with adrenal insufficiency from controls with high sensitivity (97.1%) and specificity (93.3%).
CONCLUSIONS: Salivary cortisol is a useful tool to assess endogenous cortisol excess or adrenal insufficiency and to evaluate stable CD in remission.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23610124     DOI: 10.1530/EJE-13-0159

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  23 in total

Review 1.  Cushing's Syndrome: Screening and Diagnosis.

Authors:  Filippo Ceccato; Marco Boscaro
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-09

2.  Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone.

Authors:  Tania Pilli; Sandro Cardinale; Silvia Cantara; Gilda Dalmazio; Raffaella Forleo; Marco Capezzone; Cristian Bassi; Massimo Negrini; Manuela Ferracin; Maria Grazia Castagna
Journal:  Endocrine       Date:  2021-01-08       Impact factor: 3.633

3.  Diagnostic performance of a newly developed salivary cortisol and cortisone measurement using an LC-MS/MS method with simple and rapid sample preparation.

Authors:  K Mészáros; G Karvaly; Z Márta; B Magda; J Tőke; N Szücs; M Tóth; K Rácz; A Patócs
Journal:  J Endocrinol Invest       Date:  2017-08-16       Impact factor: 4.256

4.  Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma.

Authors:  Filippo Ceccato; Mattia Barbot; Nora Albiger; Giorgia Antonelli; Marialuisa Zilio; Marco Todeschini; Daniela Regazzo; Mario Plebani; Carmelo Lacognata; Maurizio Iacobone; Franco Mantero; Marco Boscaro; Carla Scaroni
Journal:  Endocrine       Date:  2017-09-27       Impact factor: 3.633

Review 5.  Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor.

Authors:  Marco Grasso; Marco Boscaro; Carla Scaroni; Filippo Ceccato
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-11-10

Review 6.  Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.

Authors:  Sahdeo Prasad; Amit K Tyagi; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-24

7.  First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS.

Authors:  F Ceccato; G Antonelli; A C Frigo; D Regazzo; M Plebani; M Boscaro; C Scaroni
Journal:  J Endocrinol Invest       Date:  2017-02-28       Impact factor: 4.256

8.  The diagnostic accuracy of increased late night salivary cortisol for Cushing's syndrome: a real-life prospective study.

Authors:  F Ceccato; G Marcelli; M Martino; C Concettoni; M Brugia; L Trementino; G Michetti; G Arnaldi
Journal:  J Endocrinol Invest       Date:  2018-07-09       Impact factor: 4.256

9.  A venous thromboembolism risk assessment model for patients with Cushing's syndrome.

Authors:  Marialuisa Zilio; Linda Mazzai; Maria Teresa Sartori; Mattia Barbot; Filippo Ceccato; Viviana Daidone; Alessandra Casonato; Graziella Saggiorato; Franco Noventa; Laura Trementino; Paolo Prandoni; Marco Boscaro; Giorgio Arnaldi; Carla Scaroni
Journal:  Endocrine       Date:  2015-06-26       Impact factor: 3.633

10.  Midnight salivary cortisol for the diagnosis of Cushing's syndrome in a Chinese population.

Authors:  Dao-Chen Lin; Pei-Shan Tsai; Yi-Chun Lin
Journal:  Singapore Med J       Date:  2018-11-29       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.